Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

Purpose: Treatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients with advanced hormone receptor–positive, HER2-negative (HR + HER2–) breast cancer (BC). However, real-world data on the implementation of therapy usage, efficacy, and toxicity have not yet been...

Full description

Bibliographic Details
Main Authors: Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Breast
Subjects:
Advanced breast cancer
Metastatic
Chemotherapy
Endocrine therapy
CDK4/6
Ribociclib
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977620301648

Internet

http://www.sciencedirect.com/science/article/pii/S0960977620301648

Similar Items